DrugPatentWatch Database Preview
Details for Biologics License Application: 125370
Summary for BLA: 125370
| Tradename: | BENLYSTA |
| Applicant: | Human Genome Sciences Inc. |
| Ingredient: | belimumab |
| Patents: | 40 |
| Approval Date: | Mar 09, 2011 |
| Suppliers: see list | 1 |
Pharmacology for BLA: 125370
| Drug Class | B Lymphocyte Stimulator-specific Inhibitor |
| Mechanism of Action | B Lymphocyte Stimulator-directed Antibody Interactions |
| Physiological Effect | Decreased B Lymphocyte Activation |
US Patents for BLA: 125370
| Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Number | Approval Date | Patent No. | Assignee | Estimated Patent Expiration | Status | Orphan | Source |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Human Genome Sciences Inc. | BENLYSTA | belimumab | INJECTABLE; INJECTION | 125370 | 001 | 2011-03-09 | Start Trial | The United States of America, as represented by the Secretary, Department of Health & Human Services (Washington, DC) | 2038-10-10 | RX | search | |
| Human Genome Sciences Inc. | BENLYSTA | belimumab | INJECTABLE; INJECTION | 125370 | 001 | 2011-03-09 | Start Trial | CureVac AG (Tubingen, DE) | 2032-02-15 | RX | search | |
| Human Genome Sciences Inc. | BENLYSTA | belimumab | INJECTABLE; INJECTION | 125370 | 001 | 2011-03-09 | Start Trial | Exagen Diagnostics, Inc. (Vista, CA) | 2031-02-11 | RX | search | |
| >Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Number | >Approval Date | >Patent No. | >Assignee | >Estimated Patent Expiration | >Status | >Orphan | >Source |
